Key data on Merck cholesterol drug pushed to 2014

(Reuters) – Merck & Co Inc said on Wednesday it expects data from a large study designed to assess the effectiveness of its cholesterol drug Vytorin to be available in 2014, instead of 2013. The closely watched, 18,000-patient trial, called IMPROVE- IT, was designed to assess whether Merck's drug Zetia, when combined with its older cholesterol drug Zocor, is more effective in reducing heart …

Leave a Reply

Your email address will not be published.

*